ARG10194

anti-TNF alpha antibody [B1E4] (HRP)

anti-TNF alpha antibody [B1E4] (HRP) for ELISA and Human

Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody

Overview

Product Description

HRP-conjugated Mouse Monoclonal antibody [B1E4] recognizes Human TNF-alpha

Tested Reactivity Hu
Tested Application ELISA
Host Mouse
Clonality Monoclonal
Clone B1E4
Isotype IgG1, k
Target Name TNF alpha
Antigen Species Human
Immunogen Purified recombinant human TNF-α
Conjugation HRP
Full Name tumor necrosis factor
Alternate Names Tumor necrosis factor ligand superfamily member 2; DIF; Cachectin; ICD2; ICD1; N-terminal fragment; TNF-a; TNFA; TNFSF2; TNF-alpha; Tumor necrosis factor; NTF

Application Instructions

Application Note ELISA: This HRP-conjugated monoclonal antibody can be used as a tracer/detection antibody in sandwich ELISA applications for human TNF-alpha detection in combination with capture antibody CH8820 (Cat. No.: ARG10001).
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.

Properties

Form Liquid
Purification Protein G affinity purified
Buffer 0.01M PBS (pH 7.2) and 50% Glycerol
Stabilizer 50% Glycerol
Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Keep the antibody in the dark and keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database links

GeneID: 7124 Human TNF

Swiss-port # P01375 Human Tumor necrosis factor

Gene Symbol TNF
Gene Full Name tumor necrosis factor
Background Tumor Necrosis Factor alpha (TNF-α) is a multifunctional pro-inflammatory cytokine, mainly secreted by activated macrophages. TNF-α was named for its remarkable ability to cause hemorrhagic necrosis of tumors in mice. It is implicated with a variety of biological procedures including systemic inflammation, cell proliferation, apoptosis, lipid metabolism, and coagulation. The pleiotropic attribute of TNF-α regulation is associated with its ability to trigger multiple signalling pathways simultaneously. It is well documented that TNF-α functions through its receptors, TNFR1 (p55) and TNFR2 (p75). TNF-α not only contributes to the immune response to bacterial, fungal, viral and parasitic invasions, but also functions in tissue remodeling, autoimmune-diseases and the necrosis of specific tumors. TNF-α hyper-expression in response to some bacterial components such as LPS can cause life threatening septic shock. Recombinant TNF-α, in combination with chemotherapy, has been applied for treatment of soft sarcomas, melanomas and other irresectable tumors. Anti-TNF-α therapy has been used for treatment of rheumatoid arthritis.
Function Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208).
The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells. [UniProt]
Research Area Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody
PTM The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.
The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1.
O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.